Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals Limited has announced promising Phase 2 clinical trial results for NNZ-2591, showing significant improvements in children with Pitt Hopkins syndrome across all four specially designed efficacy measures. The treatment, which has no current approved alternatives, was deemed safe, well-tolerated, and displayed potential for addressing multiple neurodevelopmental disorders. The advancements mark a critical step for the company towards developing the first approved treatment for this underserved patient community.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
